An Ottawa tech firm is putting its unique DNA testing capabilities towards detecting early indicators of Alzheimer’s disease.
Spartan Bioscience announced Wednesday a partnership with the Global Alzheimer’s Platform Foundation to help recruit for clinical trials targeting the chronic neurodegenerative disease.
Spartan, known for its distinctive DNA testing cube, has developed a genetic pre-screening test capable of detecting whether subjects carry a particular gene variation that puts them at higher risk of developing Alzheimer’s. According to a release, these individuals might be “ideal clinical trial candidates” for research on the disease.
OBJ360 (Sponsored)
Howard Silver doesn’t like being in the spotlight, but he recognizes there are times when it’s important to step forward — and this is one of them. “I’m really doing
REDBLACKS linebacker loves playing in home city, but might love giving back more
As a linebacker for the Ottawa REDBLACKS, Ottawa native James Peter says he’s “extremely grateful” to be one of the rare CFL players with the opportunity to play high school,
Through the announced partnership, Spartan will also contribute $5 from each sale of its pre-screening test towards GAP’s transportation program, which providers Alzheimer’s clinical trial participants with rides to and from their appointments.
Spartan notes that its test is currently cleared for research uses only, not diagnosis.
